药石科技：公司高度重视寡核苷酸药物领域的发展机遇

Core Viewpoint - The company is focusing on the development opportunities in the oligonucleotide drug field and has established a specialized team to enhance its capabilities in this area [1] Group 1 - The company has designed a diverse range of molecular building blocks, including nucleotides, phosphoramidites, and delivery technologies, with over 500 product types currently available [1] - In the first half of this year, the company integrated internal resources to establish a professional peptide and oligonucleotide team (PTCoE) [1] - The company is accelerating its capabilities in oligonucleotide synthesis, chemical modification, conjugation, process development, and analysis [1] Group 2 - The company will continue to closely monitor industry technology development trends and will timely advance relevant layouts [1]